BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Friday, March 29, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
Oct. 3, 2012
View Archived Issues
Xention identifies novel ion channel blockers for atrial fibrillation
Read More
Seachaid Pharmaceuticals compounds active against Gram-positive bacteria
Read More
Opaxio receives FDA orphan drug designation
Read More
Coyote Pharmaceuticals plans clinical program with CNS-102
Read More
Encouraging phase III results for rFIXFc in hemophilia B
Read More
Pfizer discloses new antibacterial agents
Read More
Novel TRPM8 channel antagonists presented by Pfizer
Read More
PAC-14028 evaluated as a treatment for pruritus
Read More
The Vanderbilt University patents new mGlu5 receptor allosteric modulators
Read More
Czech scientists report novel dual PGE2 and NO production inhibitors
Read More
NuCana BioMed synthesizes new thymidylate synthase inhibitors
Read More
Phase IIb study of NBI-98854 in tardive dyskinesia commences
Read More
Eliglustat tartrate meets primary endpoint in phase III trial in Gaucher's disease
Read More
FDA panel recommends approval of Argus II Retinal Prosthesis System
Read More
Acacia Pharma reports results from phase IIa APD-403 study
Read More
IND cleared for Omeros' lead PDE10 candidate
Read More
NIAID grant awarded to AvidBiotics for antibacterial proteins
Read More
Diacomit approved in Japan for Dravet syndrome
Read More
Japanese approval granted for Buphenyl for urea cycle disorders
Read More
Delamanid can be administered with efavirenz
Read More
GTx sells Fareston
Read More
SBIR grant supports Colby Pharmaceutical's work in prostate cancer
Read More
ArQule and Daiichi Sankyo discontinue phase III MARQUEE trial
Read More
NDA submitted for vortioxetine for major depressive disorder
Read More
Janssen licenses rights to Astellas' oral JAK inhibitor
Read More
U.S. government awards GeoVax a grant for its HIV vaccine program
Read More